Pediatric Pain Management

Krane, Elliot J.; Almgren, Christina; Golianu, Brenda

doi:10.1016/b978-1-4377-0755-7.00071-3

Cited by 13 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During follow up headache diary was interpreated and assessment was done regarding headache frequency, headache days/month, VAS score and pedMIDAS. 23,24 Any side effects of the drugs were also recorded.…”

Section: Completementioning

confidence: 99%

Comparison between flunarizine and levetiracetam in paediatric migraine prophylaxis

Rahman

Kundu

Fatema³

et al. 2019

Bangladesh med. j. Khulna

View full text Add to dashboard Cite

Background:Migraine hampers child's life through school absence, limitation of home and social activities. The goal of prophylactic (preventive) therapy is to reduce headache frequency, headache days, and headache severity with minimum side effects.Objective: To evaluate the efficacy and tolerability of levetiracetam compared to flunarizine as prophylactic treatment of Migraine in children.Methods: This prospective study was carried out in the outpatient department of a tertiary care hospital in Bangladesh. A total of 105 children aged 6-15 years, diagnosed as migraine without aura, were enrolled. Patients were treated with flunarizine or levetiracetam for three months. Headache disabilities were evaluated at baseline and at the end of three months. Results:In flunarizine group, 54 children and in levetiracetam group, 51 children were enrolled. Among them thirty nine children in flunarizine group and 36 children in levetiracetam group completed the study. Headache frequency, headache days, VAS (Visual Analogue Scale) score and PedMIDAS (Paediatric Migraine Disability Assessment Score) score were evaluated at baseline and during the follow up. After three months, headache frequency, headache days, pain severity (Visual Analogue Scale score) reduced significantly compared to baseline (p<0.05). PedMIDAS score was also reduced from 60.35(±16.36) to 30.13(±14.28) in flunarizine group and from 64.25(±19.63) to 25.91(±18.6) in levetiracetam group (p<0.05). Some minor side effects were also reported by both groups, but were well tolerated by the patients and need not withdrawal of medication. Conclusion: Levetiracetam is as effective as flunarizine in paediatric MigraineProphylaxis.

show abstract

Section: Completementioning

confidence: 99%

Comparison between flunarizine and levetiracetam in paediatric migraine prophylaxis

Rahman

Kundu

Fatema³

et al. 2019

Bangladesh med. j. Khulna

View full text Add to dashboard Cite

show abstract

“…All information is processed, and modulated in the brain, where consciousness of the experience of pain takes place. 20 , 21 Patients with chronic pain present facilitation of the nociceptive circuits, with increased signal transduction and reduced response threshold to noxious stimuli, originating phenomena of peripheral and central sensitization, often without any identifiable structural cause. 20 , 21 Currently, pain is interpreted as a complex multidimensional process with the integration of biological, psychological, individual, sociocultural, and environmental factors, based on the biopsychosocial model ( Fig.…”

Section: Resultsmentioning

confidence: 99%

Chronic non-cancer pain in adolescents: a narrative review

Silva

Oliveira

Pestana-Santos

et al. 2022

Brazilian Journal of Anesthesiology (English Edition)

View full text Add to dashboard Cite

“…Children with Down syndrome may have difficulties or delays in determining the expression and location of pain 34,35 . Children with autism spectrum disorder, on the other hand have a slower response to recovery 36,37 . Since there may be fear and anxiety in families, they should be prepared by informing them before the examination and procedures 38,39 .…”

Section: Discussionmentioning

confidence: 99%

Emergency service perspective of families with children who have neurodevelopmental diseases

Hayri

Beştemir

Gülşen³

et al. 2023

CMJ

View full text Add to dashboard Cite

Introduction: It is known that children with neurodevelopmental diseases have frequent traumas like falling and apply to emergency department which significantly affects patient and family. Our aim is to examine the families' view and the problems encountered in emergency services by examining their answers to questionnaire. Method: This study was designed retrospectively. Patients registered in Department of Autism, Mental Special Needs and Rare Diseases as families with children who have neurodevelopmental diseases included in the study. 324 families’ survey with 12 open-ended questions evaluated in terms of distribution and frequencies with descriptive statistical methods. Results: By analyzing the data obtained the findings of the research were gathered under 12 main themes and 80 sub-themes. 313 (89.9%) were diagnosed with Down Syndrome, 9 (2.5%) with Angelman Syndrome, 7 (2.02%) with intellectual disability, and 5 (1.4%) with Autism. 34.2% of the children were 0-3 years old, 28.7% were 3-6 years old, 20.9% were 6-10 years old. Emergency services were used in "all cases where urgent intervention is required" (70%), and in cases where “an outpatient appointment couldn’t made" (10.8%) Conclusion: It would be beneficial to examine children with neurodevelopmental diseases in an understanding and patient manner, using a plain and understandable language, in a quiet environment in emergency room. To solve these patient’s problems, awareness training of healthcare professionals, having separate examination and observation room, ensuring accessibility and arranging the room with necessary medical supplies and equipment should be made.

show abstract

Pediatric Pain Management

Cited by 13 publications

References 24 publications

Comparison between flunarizine and levetiracetam in paediatric migraine prophylaxis

Comparison between flunarizine and levetiracetam in paediatric migraine prophylaxis

Chronic non-cancer pain in adolescents: a narrative review

Emergency service perspective of families with children who have neurodevelopmental diseases

Contact Info

Product

Resources

About